Read by QxMD icon Read


Christophe Van Berckelaer, Manon Huizing, Mireille Van Goethem, Andrew Vervaecke, Konstantinos Papadimitriou, Inge Verslegers, Bich X Trinh, Peter Van Dam, Sevilay Altintas, Tim Van den Wyngaert, Ivan Huyghe, Vasiliki Siozopoulou, Wiebren A A Tjalma
OBJECTIVE: To evaluate the role of preoperative axillary staging with ultrasound (US) and fine needle aspiration cytology (FNAC). Can we avoid intraoperative sentinel lymph node (SLN) examination, with an acceptable revision rate by preoperative staging? DESIGN: This study is based on the retrospective data of 336 patients that underwent US evaluation of the axilla as part of their staging. A FNAC biopsy was performed when abnormal lymph nodes were visualized. Patients with normal appearing nodes on US or a benign diagnostic biopsy had removal of the SLNs without intraoperative pathological examination...
September 20, 2016: European Journal of Obstetrics, Gynecology, and Reproductive Biology
Hiram S Cody
No abstract text is available yet for this article.
September 30, 2016: Annals of Surgical Oncology
J M Mann, X Wu, P Christos, D Nori, S C Formenti, H Nagar
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Dalliah Black
Axillary ultrasound is increasingly utilized for nodal staging preoperatively in patients presenting with invasive breast cancer to provide guidance for preoperative chemotherapy or proceeding directly to surgery. Improvements in ultrasound technology make it possible to assess the nodal burden in order to identify those patients not eligible for ACOSOG Z0011 management. However, its ability to detect metastasis is variable and dependent on operator's skills, size of metastatic deposit, and primary tumor histology subtype...
August 24, 2016: Annals of Surgical Oncology
Yasuhiro Tamaki
The one-step nucleic acid amplification (OSNA) assay was initially developed for the intraoperative assessment of sentinel lymph node metastases in breast cancer. This assay measures cytokeratin 19 (CK19) mRNA copy number and is widely used in hospitals. The results of the IBCSG 23-01, ACOSOG Z0011, and AMAROS trials demonstrated that no further axillary dissection is required for patients with sentinel lymph nodes that tested positive for cancer, which has led to a decreasing trend in the need for intraoperative assessment of lymph nodes...
August 22, 2016: International Journal of Clinical Oncology
Armando E Giuliano, Karla Ballman, Linda McCall, Peter Beitsch, Pat W Whitworth, Peter Blumencranz, A Marilyn Leitch, Sukamal Saha, Monica Morrow, Kelly K Hunt
BACKGROUND AND OBJECTIVE: The early results of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial demonstrated no difference in locoregional recurrence for patients with positive sentinel lymph nodes (SLNs) randomized either to axillary lymph node dissection (ALND) or sentinel lymph node dissection (SLND) alone. We now report long-term locoregional recurrence results. METHODS: ACOSOG Z0011 prospectively examined overall survival of patients with SLN metastases undergoing breast-conserving therapy randomized to undergo ALND after SLND or no further axillary specific treatment...
September 2016: Annals of Surgery
Kalnisha Naidoo, Sarah E Pinder
Pathologists typically examine the sentinel lymph nodes excised from patients with invasive breast cancer more thoroughly than they have historically those from axillary lymph node clearance specimens. This, it is thought, increases the chances of detecting small metastatic foci (i.e. macrometastases (>2 mm), micrometastases (0.2-2 mm), or isolated tumour cell clusters (<0.2 mm or <200 cancer cells in one section)). However, the clinical significance of these small metastatic deposits remains unclear...
August 3, 2016: Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
Viet H Le, Kathleen N Brant, Dawn W Blackhurst, Christine M G Schammel, David P Schammel, Wendy R Cornett, Brian P McKinley
BACKGROUND: Axillary dissection (AD) was historically recommended for all patients with breast tumor involvement discovered by sentinel lymph node biopsy (+SLNB). However, after the ACOSOG Z0011 trial, omission of AD became the recommendation for selected patients with a +SLNB. We report the impact of ACOSOG Z0011 on the completion AD rate in patients with +SLNB at our institution. METHODS: We retrospectively reviewed all patients diagnosed with breast cancer between March 2009 and February 2013 (n = 1781)...
October 2016: Breast: Official Journal of the European Society of Mastology
Corrado Tinterri, Giuseppe Canavese, Paolo Bruzzi, Beatrice Dozin
Sentinel lymph node biopsy alone is the current surgical axillary treatment for early-stage breast cancer patients with a negative sentinel lymph node (SLN). The possibility to omit axillary dissection also in presence of positive SLNs has been promoted by the American College of Surgeons Oncology Group (ASOCOG) Z0011 randomized trial. Several limitations and evidences of potential selection bias made this trial fairly controversial. Stronger evidence than currently available is needed on the safety of foregoing axillary dissection in well-defined populations of patients with positive SLNs...
July 9, 2016: Breast: Official Journal of the European Society of Mastology
Julie M Jorns, Kelley M Kidwell
OBJECTIVES: To evaluate use of sentinel lymph node (SLN) frozen section (FS) before and after publication of the Z0011 trial. METHODS: We identified 116 pre-Z0011 and 134 post-Z0011 patients from 18 months before and after Z0011-initiated changes. Clinicopathologic features were assessed by chart review. RESULTS: Post-Z0011 SLN FS use markedly declined when performed with breast-conserving therapy (BCT) (P < .0001), with SLN FS in 53 (73...
July 2016: American Journal of Clinical Pathology
Miriam W Tsao, Sylvie D Cornacchi, Nicole Hodgson, Marko Simunovic, Lehana Thabane, Ji Cheng, Mary Ann O'Brien, Barbara Strang, Som D Mukherjee, Peter J Lovrics
INTRODUCTION: Evidence from the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial suggests completion axillary lymph node dissection (cALND) after positive sentinel lymph node biopsy (+SLNB) does not improve outcomes in select patients, leading to practice variation. A multidisciplinary group of surgeons, oncologists, and pathologists developed a regional guideline for cALND which was disseminated in August 2012. We assessed the impact of Z0011 and the regional guideline on cALND rates...
October 2016: Annals of Surgical Oncology
N C Verheuvel, A C Voogd, V C G Tjan-Heijnen, R M H Roumen
BACKGROUND: The ACOSOG Z0011 trial, a randomized controlled trial among patients with sentinel node positive breast cancer treated with breast conserving therapy, concluded that axillary lymph node dissection (ALND) can be omitted in these patients. However, questions were raised on the general applicability if the results of the Z0011 trial. Therefore, the aim of this study was to assess the practice changing effect of the Z0011 trial by quantifying the proportion of all node positive breast cancer patients who meet the inclusion criteria which are based on the Z0011 trial, thus in whom an ALND could be omitted...
August 2016: European Journal of Surgical Oncology
Anita Mamtani, Sujata Patil, Kimberly J Van Zee, Hiram S Cody, Melissa Pilewskie, Andrea V Barrio, Alexandra S Heerdt, Monica Morrow
BACKGROUND: The American College of Surgeons Oncology Group Z0011 trial demonstrated the safety of omitting axillary lymph node dissection (ALND) for women with fewer than three positive sentinel lymph nodes (SLNs) who are undergoing breast-conservation therapy (BCT). Because most of the women were postmenopausal with estrogen receptor (ER) positive cancers, applicability of ALND for younger patients and those with triple-negative (TN) or human epidermal growth factor receptor 2 (HER2) overexpressing (HER2+) tumors remains controversial...
October 2016: Annals of Surgical Oncology
N C Verheuvel, H W A Ooms, V C G Tjan-Heijnen, R M H Roumen, A C Voogd
PURPOSE: Various prediction models have been developed to predict the risk of having no additional axillary metastases in patients with a positive sentinel lymph node biopsy (SLNB), thereby disregarding patients with a positive ultrasound-guided lymph node biopsy (UGLNB). However, in the post-Z0011 trial era it is important to identify all patients with extensive nodal involvement for whom axillary treatment might still be beneficial. Therefore, the aim of this study is to identify factors predicting extensive nodal involvement (≥3 positive nodes) in the axilla, with the emphasis on the method of axillary staging: node positivity by UGLNB versus SLNB...
June 2016: Breast: Official Journal of the European Society of Mastology
Emma Gannan, Jeremy Khoo, Sophie Nightingale, Thomas Surya Suhardja, Jocelyn Lippey, Holly Keane, Kian Jin Tan, David Clouston, Alexandra Gorelik, Gregory Bruce Mann
To examine practice patterns for breast cancer patients with limited sentinel node (SN) disease in light of the ACOSOG Z0011 results. Retrospective analysis of patients with T1-2 breast cancer and positive sentinel lymph node biopsy (SLNB) admitted between January 2009 and December 2012. Patient demographics, tumor characteristics, and treatments were recorded. Eight hundred positive SLNBs were identified. A total of 452 (56.5%) proceeded to completion axillary lymph node dissection (cALND). cALND rate decreased from 65...
July 2016: Breast Journal
Emmanuel Gabriel, Kristopher Attwood, Jessica Young, Helen Cappuccino, Shicha Kumar
BACKGROUND: The application of the American College of Surgeons Oncology Group Z0011 trial (Z11) has resulted in fewer completion axillary lymph node dissections (ALNDs) for select patients. We hypothesize that the application of Z11 may result in fewer ALND cases for surgeons in training. METHODS: In the setting of an academic cancer center incorporating Z11 into routine practice, we compared the total number of ALND performed in a pre-Z11 period (January 2007-April 2011, 52 mo) and post-Z11 period (April 2011-February 2014, 34 mo)...
April 2016: Journal of Surgical Research
Ying Zhu, Wei Zhou, Jian-Qiao Zhou, Xiao-Chun Fei, Ting-Jun Ye, Ou Huang, Xiao-Song Chen, Wei-Wei Zhan
OBJECTIVES: Ultrasound (US)-guided fine-needle aspiration cytology (FNAC) is able to identify patients with extensive node involvement before surgery. In this study, we aimed to establish the optimal US criterion to identify abnormal lymph nodes on US-guided FNAC for detection of patients with 3 or more metastatic axillary nodes. METHODS: A total of 445 axillae from 443 patients with histologically confirmed invasive breast cancer (cT1-2 cN0) were examined with US at Ruijin Hospital from August 2013 to August 2014...
May 2016: Journal of Ultrasound in Medicine: Official Journal of the American Institute of Ultrasound in Medicine
G M Kramer, M W H Leenders, L J Schijf, H L S Go, T van der Ploeg, M P van den Tol, W H Schreurs
This study evaluated the accuracy of ultrasound-guided fine-needle aspiration cytology of the sonographically most suspicious axillary lymph node (US/FNAC) to select early breast cancer patients with three or more tumour-positive axillary lymph nodes. Between 2004 and 2014, a total of 2130 patients with histologically proven early breast cancer were evaluated and treated in the Noordwest Clinics Alkmaar. US/FNAC was performed preoperatively in all these patients. We analysed the results of US/FNAC retrospectively...
April 2016: Breast Cancer Research and Treatment
Adam Gondos, Lina Jansen, Jörg Heil, Andreas Schneeweiss, Adri C Voogd, Jan Frisell, Irma Fredriksson, Ulla Johansson, Tove Filtenborg Tvedskov, Maj-Britt Jensen, Eva Balslev, Olaf Johan Hartmann-Johnsen, Milena Sant, Paolo Baili, Roberto Agresti, Tony van de Velde, Annegien Broeks, Jean-Marie Nogaret, Pierre Bourgeois, Michel Moreau, Zoltán Mátrai, Ákos Sávolt, Péter Nagy, Miklós Kásler, Petra Schrotz-King, Cornelia Ulrich, Hermann Brenner
Background We examined time trends in axilla management among patients with early breast cancer in European clinical settings. Material and methods EUROCANPlatform partners, including population-based and cancer center-specific registries, provided routinely available clinical cancer registry data for a comparative study of axillary management trends among patients with first non-metastatic breast cancer who were not selected for neoadjuvant therapy during the last decade. We used an additional short questionnaire to compare clinical care patterns in 2014...
June 2016: Acta Oncologica
Timothy C Kenny, James Dove, Mohsen Shabahang, Nicole Woll, Marie Hunsinger, April Morgan, Joseph Blansfield
The ACOSOG Z0011 trial demonstrated that axillary lymph node dissection (ALND) is not necessary for all breast cancer patients. Patients who underwent breast conservation surgery (BCS) or total mastectomy (TM) and met Z0011 criteria were identified and sorted into pre- and post- Z0011 cohorts. Four hundred ninety four patients had breast cancer surgery from July 2008 to February 2013. Of these, 255 were pre-Z0011 and 239 were post. Pre-Z0011, 14 patients met Z0011 inclusion criteria in BCS subgroup. ALND was performed in 10 of these patients (71%)...
January 2016: American Surgeon
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"